ResearcherInsermActive in the last 2 years
Salem Chouaı̈b
Matched on ORCID iD 0009-0007-3228-6882; OpenAlex author ID A5045530749. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 4)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 16
2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 2 papers
Papers 6
- Hypoxic Tumor Microenvironment Targeting: Opportunities and Challenges for Pancreatic Cancer Immunotherapy. Last author DOI 10.3390/ijms27093873↗
- Hypoxia Differentially Regulates Ferroptosis Sensitivity and Tumor Cell-Intrinsic Type I Interferon Signaling in Pancreatic Ductal Adenocarcinoma Cells. Last author DOI 10.3390/ijms27146397↗
- Hypoxia, a Targetable Culprit to Counter Pancreatic Cancer Resistance to Therapy. Last author DOI 10.3390/cancers15041235↗
- An Eight-Gene Hypoxia Signature Predicts Survival in Pancreatic Cancer and Is Associated With an Immunosuppressed Tumor Microenvironment. Last author DOI 10.3389/fimmu.2021.680435↗
- Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment. Co-author DOI 10.3389/fimmu.2018.01044↗
- BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC). Co-author DOI 10.1080/2162402x.2017.1372080↗
Closest collaborators
The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Raefa Abou Khouzam · 3 shared papers, 2021–2026 · strength 0.64
- Paper Hypoxic Tumor Microenvironment Targeting: Opportunities and Challenges for Pancreatic Cancer Immunotherapy. DOI 10.3390/ijms27093873↗
- Paper Hypoxia, a Targetable Culprit to Counter Pancreatic Cancer Resistance to Therapy. DOI 10.3390/cancers15041235↗
- Paper An Eight-Gene Hypoxia Signature Predicts Survival in Pancreatic Cancer and Is Associated With an Immunosuppressed Tumor… DOI 10.3389/fimmu.2021.680435↗
- Përparim Limani · 2 shared papers, 2023–2026 · strength 0.51
- Shubhankar Das · 1 shared paper, 2026 · strength 0.50
- Pierre‐Alain Clavien · 1 shared paper, 2023 · strength 0.19
- Michel Pierre Ducreux · 1 shared paper, 2023 · strength 0.19
- Michael B. Wallace · 1 shared paper, 2023 · strength 0.19
- Etienne D. Foucher · 2 shared papers, 2017–2018 · strength 0.15
- Paper Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment. DOI 10.3389/fimmu.2018.01044↗
- Paper BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocar… DOI 10.1080/2162402x.2017.1372080↗
- Daniel Olive Directeur · 2 shared papers, 2017–2018 · strength 0.15
- Paper Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment. DOI 10.3389/fimmu.2018.01044↗
- Paper BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocar… DOI 10.1080/2162402x.2017.1372080↗
- Juan Iovanna · 2 shared papers, 2017–2018 · strength 0.15
- Paper Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment. DOI 10.3389/fimmu.2018.01044↗
- Paper BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocar… DOI 10.1080/2162402x.2017.1372080↗
- Céline Loncle · 1 shared paper, 2017 · strength 0.06
- Véronique Secq · 1 shared paper, 2017 · strength 0.06
- Elena Vila-Navarro · 1 shared paper, 2017 · strength 0.06
- Jean–Charles Dagorn · 1 shared paper, 2017 · strength 0.06
- Audrey Benyamine · 1 shared paper, 2017 · strength 0.06
- Meritxell Gironella · 1 shared paper, 2017 · strength 0.06
- Nelson Dusetti · 1 shared paper, 2017 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.